PharmTech Drug Digest 11.20
|Articles|May 7, 2009

Sanofi-aventis Plans Biopharmaceutical Investment

Sanofi-aventis introduced this week its Biolaunch project at its Vitry-sur-Seine, France, pharmaceutical production site.

Sanofi-aventis introduced this week its Biolaunch project at its Vitry-sur-Seine, France, pharmaceutical production site. The nearly EUR 200-million ($266 million) investment will be used to provide the company with its first cell-culture platform to produce monoclonal antibodies.

Sanofi-aventis plans to have the project completed by 2012 and to transfer current chemical activities at the Vitry-sur-Seine site by 2011. The Biolaunch project is part of a long-term approach by the company to invest in biotechnology. It is part of plan to convert the Vitry-sur-Seine site into a biotechnology facility that includes research, development, and production activities.

Investment in China
In other news, sanofi-aventis also announced that it will relocate its current manufacturing facility in downtown Hangzhou, Zhejiang Province, China, and build a new site in the Binjiang New Development Zone in Hangzhou. The company is investing approximately EUR 31 million ($41 million).

The new 44,775-m2 site is scheduled to be completed by 2012 and have an expanded capacity of 160 million packs. The current plant produces and packs the company’s major cardiovascular and anticancer products, including Plavix, Aprovel/Co-Aprovel, Taxotere, and Eloxatin.


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.